Company intelligence / Profile preview

NMSCMS

Nerviano, Lombardy, Italynmscms.com ↗

Ownership: Private
Employees: ~400
Development stage: Commercial

Overview

Nerviano Medical Sciences has a robust pipeline with more than a dozen anti-cancer projects. Three are currently in early clinical development. The company has successfully outlicensed assets such as entrectinib (Rozlytrek®), encorafenib (Braftovi®), and onvansertib that have reached commercialization or late-stage trials through partners. Recent IND clearance was received for NMS‑812, a first-in-class dual PERK/GCN2 inhibitor.

Therapeutic areas: Oncology
Modalities: Small moleculeAntibody-drug conjugateBiologic
Industry: Biotech

Drug pipeline

1 asset

Nectin-4 ADC

Preclinical

Partnerships

RochePfizerCardiff Oncology

Beyond the preview

Go deeper on NMSCMS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NMSCMS.

Explore the full profile